Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC

Inclusion Criteria: * Advanced HCC (BCLC stage C, or CNLC IIIa and IIIb ) with diagnosis confirmed by histology/cytology or clinically * Patients who have Tumor recurrence after surgical resection or ablation are allowed to be included * At least one measurable intrahepatic target lesion * Child-Pugh class A/B * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of at least 3 months Exclusion Criteria: * Obstructive portal vein tumor thrombus involving both the left and right portal vein or main portal vein without collateral vessels * Vascular invasion involving inferior vena cava * Central nervous system metastasis * Patients who received prior systemic therapy, immunotherapy, TACE, transcatheter arterial radioembolization (TARE), transcatheter arterial embolization (TAE), hepatic arterial infusion chemotherapy (HAIC) or radiation therapy for HCC * History of organ and cell transplantation * History of bleeding from esophageal and gastric varices * History of hepatic encephalopathy * hematologic examination: white blood cell count \<3.0×10\^9/L, platelets \<50×10\^9/L * Prothrombin time prolongation ≥ 4s * Severe organ (heart, lung, kidney) dysfunction * History of malignancy other than HCC * Active hepatitis B or C infection; hepatitis B virus (HBV) DNA \> 1000 copies/ml; hepatitis C virus (HCV) RNA \> 1000 copies/ml. Those who possess the indicators lower than the above criteria after nucleotide antiviral treatment can be enrolled